Can dupixent calm mysterious skin flares?
NCT ID NCT06012448
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested the drug dupilumab (Dupixent) in 10 people with a chronic skin condition called dermal hypersensitivity reaction. Participants received injections of dupilumab every two weeks for 24 weeks. Researchers looked at changes in immune cells in the skin and how much body surface area was affected. The goal was to learn if dupilumab is safe and could help treat this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dupilumab (Dupixent)
- What this could lead to
- If it works, this could point toward a treatment for chronic dermal hypersensitivity reaction, a skin condition with no standard therapy.
- What could go wrong
- This is a very small, early-phase study with only 10 participants, so results may not apply to everyone. The drug may not improve symptoms or could cause side effects like injection reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMAL HYPERSENSITIVITY REACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan
Ann Arbor, Michigan, 48109, United States